Vaccines for Africa 'face 700% mark-up'

Jonathan Miller
Sunday 18 November 2007 01:00 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Drugs companies could receive mark-ups of 700 per cent under a plan, spearheaded by Gordon Brown, to fund the development of a vaccine aimed at saving millions of children's lives in developing countries. Of £750m donated for the scheme 80 per cent will go in profits to the companies, according to one expert.

Under an "advance market commitment" governments in the developed world pay production costs, plus an agreed margin, to help provide incentives for the pharmaceuticals industry to develop such drugs.

The plan is to produce a vaccine for pneumococcal disease, which causes pneumonia, Africa's worst child-killer. US drugs giant Wyeth already manufactures the vaccine for Europe and America, creating a £1bn market in which it is about to be joined by Britain's GlaxoSmithKline. Since both companies have already developed vaccines to cover the strains most prevalent in Africa, critics say their costs will be negligible. Even though a hefty discount has been negotiated experts say millions more children could be treated if the industry accepted a lower margin.

Jonathan Miller's investigation into the vaccine plan will be broadcast on Channel 4 News tomorrow

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in